Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
Abstract Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice. Methods A propensity score analysis was performed to eliminate imbalances between the treatment groups. In the an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70158 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206499142533120 |
|---|---|
| author | Petra Belohlavkova Daniela Zackova Hana Klamova Edgar Faber Michal Karas Lukas Stejskal Eduard Cmunt Olga Cerna Ivana Jeziskova Katerina Machova Polakova Pavel Zak Tereza Jurkova Marika Chrapava Jiri Mayer |
| author_facet | Petra Belohlavkova Daniela Zackova Hana Klamova Edgar Faber Michal Karas Lukas Stejskal Eduard Cmunt Olga Cerna Ivana Jeziskova Katerina Machova Polakova Pavel Zak Tereza Jurkova Marika Chrapava Jiri Mayer |
| author_sort | Petra Belohlavkova |
| collection | DOAJ |
| description | Abstract Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice. Methods A propensity score analysis was performed to eliminate imbalances between the treatment groups. In the analysis, 163 patients in the nilotinib group and 163 patients in the matched imatinib group were retrospectively evaluated. Results Nilotinib‐treated patients achieved complete cytogenetic response (CCyR) and major molecular response more rapidly than imatinib‐treated patients. However, there was no significant difference in 5‐year overall survival (OS) or progression‐free survival (PFS) between the two groups (OS: 94.3% vs. 90.5%, p = 0.602; PFS: 92.9% vs. 88.0%, p = 0.614). Nilotinib‐treated patients had a higher failure‐free survival (FFS) and event‐free survival (EFS) than imatinib‐treated patients (FFS: 71.7% vs. 54.3%, p = 0.040; EFS: 71.7% vs. 53.5%, p = 0.025). Conclusions This retrospective analysis from clinical practice did not confirm any benefit of frontline nilotinib treatment for OS and PFS; however, it did demonstrate higher FFS and EFS in the nilotinib cohort. |
| format | Article |
| id | doaj-art-a3f1e095df1743329fc066dd5daac827 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-a3f1e095df1743329fc066dd5daac8272025-02-07T09:08:08ZengWileyCancer Medicine2045-76342024-09-011317n/an/a10.1002/cam4.70158Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life dataPetra Belohlavkova0Daniela Zackova1Hana Klamova2Edgar Faber3Michal Karas4Lukas Stejskal5Eduard Cmunt6Olga Cerna7Ivana Jeziskova8Katerina Machova Polakova9Pavel Zak10Tereza Jurkova11Marika Chrapava12Jiri Mayer134th Department of Internal Medicine and Haematology University Hospital Hradec Kralove and Charles University Prague Czech RepublicDepartment of Internal Medicine–Haematology and Oncology University Hospital Brno and Masaryk University Brno Czech RepublicInstitute of Haematology and Blood Transfusion Prague Czech RepublicDepartment of Haemato‐oncology University Hospital Olomouc and Palacky University Olomouc Czech RepublicDepartment of Haemato‐oncology University Hospital Plzen and Charles University Plzen Czech RepublicDepartment of Haemato‐oncology University Hospital Ostrava and Ostrava University Ostrava Czech Republic1st Department of Internal Medicine—Haematology General University Hospital and Charles University Prague Czech RepublicDepartment of Internal Medicine—Haematology University Hospital Kralovske Vinohrady and Charles University Prague Czech RepublicDepartment of Internal Medicine–Haematology and Oncology University Hospital Brno and Masaryk University Brno Czech RepublicInstitute of Haematology and Blood Transfusion Prague Czech Republic4th Department of Internal Medicine and Haematology University Hospital Hradec Kralove and Charles University Prague Czech RepublicInstitute of Biostatistics and Analyses Masaryk University Brno Czech RepublicInstitute of Biostatistics and Analyses Masaryk University Brno Czech RepublicDepartment of Internal Medicine–Haematology and Oncology University Hospital Brno and Masaryk University Brno Czech RepublicAbstract Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice. Methods A propensity score analysis was performed to eliminate imbalances between the treatment groups. In the analysis, 163 patients in the nilotinib group and 163 patients in the matched imatinib group were retrospectively evaluated. Results Nilotinib‐treated patients achieved complete cytogenetic response (CCyR) and major molecular response more rapidly than imatinib‐treated patients. However, there was no significant difference in 5‐year overall survival (OS) or progression‐free survival (PFS) between the two groups (OS: 94.3% vs. 90.5%, p = 0.602; PFS: 92.9% vs. 88.0%, p = 0.614). Nilotinib‐treated patients had a higher failure‐free survival (FFS) and event‐free survival (EFS) than imatinib‐treated patients (FFS: 71.7% vs. 54.3%, p = 0.040; EFS: 71.7% vs. 53.5%, p = 0.025). Conclusions This retrospective analysis from clinical practice did not confirm any benefit of frontline nilotinib treatment for OS and PFS; however, it did demonstrate higher FFS and EFS in the nilotinib cohort.https://doi.org/10.1002/cam4.70158chronic myeloid leukemiafirst‐line treatmentimatinibnilotinib |
| spellingShingle | Petra Belohlavkova Daniela Zackova Hana Klamova Edgar Faber Michal Karas Lukas Stejskal Eduard Cmunt Olga Cerna Ivana Jeziskova Katerina Machova Polakova Pavel Zak Tereza Jurkova Marika Chrapava Jiri Mayer Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data Cancer Medicine chronic myeloid leukemia first‐line treatment imatinib nilotinib |
| title | Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data |
| title_full | Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data |
| title_fullStr | Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data |
| title_full_unstemmed | Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data |
| title_short | Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data |
| title_sort | clinical efficacy and safety of first line nilotinib or imatinib therapy in patients with chronic myeloid leukemia nationwide real life data |
| topic | chronic myeloid leukemia first‐line treatment imatinib nilotinib |
| url | https://doi.org/10.1002/cam4.70158 |
| work_keys_str_mv | AT petrabelohlavkova clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT danielazackova clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT hanaklamova clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT edgarfaber clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT michalkaras clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT lukasstejskal clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT eduardcmunt clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT olgacerna clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT ivanajeziskova clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT katerinamachovapolakova clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT pavelzak clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT terezajurkova clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT marikachrapava clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata AT jirimayer clinicalefficacyandsafetyoffirstlinenilotiniborimatinibtherapyinpatientswithchronicmyeloidleukemianationwidereallifedata |